中国临床药理学杂志Issue(24)：2465-2467,2470,4.DOI:10.13699/j.cnki.1001-6821.2015.24.030
达比加群酯抗凝治疗安全性的系统评价
Systematic evaluation on the safety of dabigatran for anticoagulant therapy
孙秀波 1铁远 2陈晴 1何祎晨 2刘蕾1
作者信息
- 1. 北京医院药学部，北京 100730
- 2. 北京大学 医学部 药学院药事管理与临床药学系，北京 100191
- 折叠
摘要
Abstract
Objective To evaluate the safety of dabigatran etexilate in the anticoagulant therapy.Methods The randomized controlled trials about dabigatran etexilate in the treatment of all kinds of embolism disea-ses, which had been published from the time of library foundation to June, 2015 were collected from PubMed, ClinicalTrials.gov, CNKI data-base according to the following criterias.An the same time results of studies were analyzed through using Stata 13.1 software and Rev Man 5.3 software.Results Sixteen randomized controlled trials were includ-ed, involving 42395 patients.Meta -analysis showed that dabigatran etexilate could significantly reduce the incidence of major bleeding com-paring with comparators ( P<0.05 ) , especially compared with warfarin ( P<0.01 ) .However the incidence of major bleeding with dabigatran etexilate was similar to comparators when the dosage was increased. Moreover dabigatran etexilate could significantly increase the risk of myo-cardial infarction ( P <0.01 ) , especially compared with warfarin (P<0.01).while the incidence of myocardial infarction with dabigatran etexilate was increased with the increase of the dosage.In addition dabig-atran etexilate could significantly increase the incidence of gastrointestinal bleeding ( P <0.01 ) , especially compared with warfarin and placebo ( P<0.05) , which was dose-dependent.There was no publication bias in funnel plots and sensitivity analysis indicated the results were reliable. Conclusion The use of dabigatran etexilate was associated with a significant increase in the risk of myocardial infarc-tion and gastrointestinal bleeding.Therefore, clinicians need to take these risks into account in treatment.关键词
达比加群酯/对照药/安全性/系统评价Key words
dabigatran etexilate/comparator/safety/systematic review分类
医药卫生引用本文复制引用
孙秀波,铁远,陈晴,何祎晨,刘蕾..达比加群酯抗凝治疗安全性的系统评价[J].中国临床药理学杂志,2015,(24):2465-2467,2470,4.
